MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

SM-164

CAS No. : 957135-43-2

MCE 站：SM-164

产品活性：SM-164 是一种可渗透细胞的 Smac 类似物。SM-164 与含有 BIR2 和 BIR3 结构域的 XIAP 蛋白结合，IC₅₀ 值为 1.39 nM，SM-164 用作 XIAP 的强效拮抗剂。

研究领域：Apoptosis

作用靶点：IAP  |  Apoptosis

In Vitro: SM-164 is a non-peptide, cell-permeable, bivalent small-molecule, which mimics Smac protein for targeting XIAP. SM-164 binds to XIAP containing both BIR domains with an IC₅₀ value of 1.39 nM, being 300 ａnd 7000-times more potent than its monovalent counterparts ａnd the natural Smac AVPI peptide, respectively. SM-164 concurrently interacts with both BIR domains in XIAP ａnd functions as an ultra-potent antagonist of XIAP in both cell-free functional ａnd cell-based assays. SM-164 targets cellular XIAP ａnd effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells, while having a minimal toxicity to normal human primary cells at 10,000 nM. The binding affinities of SM-164 to XIAP, cIAP-1, ａnd cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 has a K_i value of 0.56 nM to XIAP protein containing both BIR2 ａnd BIR3 domains. SM-164 has a K_i value of 0.31 nM to cIAP-1 protein containing both BIR2 ａnd BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with K_i values of 1.1 nM. Addition of exogenous TNFα can significantly enhance the activity of these Smac mimetics, especially for SM-164, in resistant cancer cell lines such as HCT116 ａnd MDA-MB-453.

In Vivo: SM-164 is evaluated for its ability to inhibit tumor growth. SM-164 is highly effective in inhibition of tumor growth ａnd capable of achieving tumor regression in the MDA-MB-231 xenograft model. Treatment with SM-164 at 1 mg/kg completely inhibits tumor growth during the treatment. Treatment with SM-164 at 5 mg/kg reduces the tumor volume from 147±54 mm³ at the beginning of the treatment (day 25) to 54±32 mm³ at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long lasting ａnd not transient. SM-164 at 5 mg/kg is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm³ (P<0.02).

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Peptidomimetic Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  SY-5609  |  BRD4 Inhibitor-18  |  8α-Tigloyloxyhirsutinolide 13-O-acetate  |  AAPK-25  |  Dutasteride-¹³C₆  |  Oleic acid-¹³C  |  Anticancer agent 120  |  Abacavir sulfate  |  Meloxicam-d₃-1  |  Thailanstatin D  |  SB-218078  |  Toyocamycin  |  Sorafenib-d₄  |  Busulfan  |  PTC-028  |  Dinaciclib  |  CR-1-31-B  |  142I5  |  Farudodstat  |  Ecteinascidin 770  |  AT9283  |  Staurosporine  |  SNS-032  |  AZA1  |  Antitumor agent-96  |  Bleomycin A5  |  Xevinapant  |  Mangiferin  |  Cambinol  |  hGGPPS-IN-1

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。